

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

LUPUS CORA 2021 Preliminary Timetable

**The congress will take place in Central European Summer Time (CEST)*

Wednesday, 6 October 2021

Hall 1		
CEST (UTC+2 Paris, Amsterdam, Berlin) 11:15–12:15 hours / EDT (UTC-4 New York, Montreal) 5:15 – 6:15 hours / CST (UTC+8 Beijing, Manila, Perth) 17:15 – 18:15 hours		
Industry Symposium		
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:15–13:45 hours / EDT (UTC-4 New York, Montreal) 6:15 – 7:45 hours / CST (UTC+8 Beijing, Manila, Perth) 18:15 – 19:45 hours		
<p>Opening Ceremony & Keynote Lecture Welcome to LUPUS 2021 Welcome to CORA 2021 Keynote lecture Chairs: Andrea Doria, Marta Mosca, Marcello Govoni How the discovery of antiphospholipid antibodies has changed lupus life Angela Tincani (Italy)</p>		
Short break		
CEST (UTC+2 Paris, Amsterdam, Berlin) 14:00–16:00 hours / EDT (UTC-4 New York, Montreal) 8:00 – 10:00 hours / CST (UTC+8 Beijing, Manila, Perth) 20:00 – 22:00 hours		
<p>Parallel 1 SLE Pathogenic insights and implications for treatment Chairs: Carlo Chizzolini (CH), Lindsay Criswell (USA) 1. BAFF in systemic lupus erythematosus. TBA 2. New insights into the role of B lineage cells in SLE. Thomas Dörner (Germany) 3. What we are learning from single cell analyses of renal myeloid cells in lupus nephritis – from mouse to human. Anne Davidson (USA) +3 oral presentations</p>	<p>Parallel 2 SLE Disease activity and outcome measures in SLE Chairs: Eric Morand (Australia), Ian Bruce; UK 1. New Insights into Activity, Organ Damage and Co-Morbidity of SLE. M Petri (USA) 2. New perspective in measuring disease activity and in defining T2T goals. L Sousa-Inês (PT) 3. The patient’s view in the disease assessment. Chiara Tani (IT) +3 oral presentations</p>	<p>Parallel 3 SLE NeuroSLE Chairs: M Govoni (IT), DT Boumpas (GR) 1. Neuroimaging as a biomarker in NPSLE. A Bortoluzzi (IT) 2. Neuropathogenic autoantibodies in SLE. B Diamond (USA) 3. Vagus Nerve Stimulation Reduces Pain and Fatigue in Patients with SLE. C Aranow (USA) +3 oral presentations</p>
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:00–16:30 hours / EDT (UTC-4 New York, Montreal) 10:00 – 10:30 hours / CST (UTC+8 Beijing, Manila, Perth) 22:00 – 22:30 hours		
Networking break		
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:30–18:00 hours / EDT (UTC-4 New York, Montreal) 10:30 – 12:00 hours / CST (UTC+8 Beijing, Manila, Perth) 22:30 – 24:00 hours		

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

Plenary 1: When should we use the new drugs in lupus nephritis?

Chair: Andrea Doria, Italy

Introduction: Andrea Doria, Italy

Voclosporin: Brad H Rovin (USA)

Belimumab: F Houssiau, Brussels (BE)

Obinutuzumab: Richard Furie (USA)

Panel discussion: Brad H Rovin (USA), F Houssiau (BE), R Furie (USA), Maria Dal'Era (USA), T M Chan (Hong Kong), D Jayne (UK), HJ Anders (DE)

Summary: Andrea Doria (Italy)

Short break

CEST (UTC+2 Paris, Amsterdam, Berlin) 18:15–19:15 hours / EDT (UTC-4 New York, Montreal) 12:15 – 13:15 hours / CST (UTC+8 Beijing, Manila, Perth) 00:15 – 01:50 hours

Industry Symposium

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

Thursday, 7 October 2021

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 08:00–09:00 hours / EDT (UTC-4 New York, Montreal) 2:00 – 3:00 hours / CST (UTC+8 Beijing, Manila, Perth) 14:00 – 15:00 hours				
Meet the Professor 1 Biologics in SLE: Josef Smolen - Vienna (AT)	Meet the Professor 2 Comorbidities and SLE: Sandra Navarra (Philippines)	Workshop 1 Lupus nephritis F Houssiau (BE)	Workshop 2 Cutaneous lupus lesions A Kuhn (DE)	Meet the Professor (CORA) 1 Jak-inhibitors in rheumatoid arthritis Ernest Choy (UK)
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours / EDT (UTC-4 New York, Montreal) 3:00 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours				
Plenary 2: Antimalarials are useful but rather weak medications for SLE Chair: E. Morand (Australia) Introduction: E. Morand (Australia) Yes, it is true. Ronald F. Van Vollenhoven, The Netherlands Vs. No, it is not true. Nathalie Costedoat-Chalumeau, France Panel discussion Summary: E. Morand (Australia)				
CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–11:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 5:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 17:00 hours				
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions				
CEST (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00 hours / EDT (UTC-4 New York, Montreal) 5:00 – 7:00 hours / CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours				
Parallel 4 SLE Arthritis, vaccines and COVID-19 in SLE Chairs: L Czirjak (HU), S Navarra (The Phillipines) 1. Predicting erosive arthritis in SLE. Fabrizio Conti (Italy) 2. Vaccination in SLE. CC Mok (Hong Kong) 3. Poor prognosis of COVID-19 ARDS in SLE. E Bonfá (Brazil) +3 oral presentations	Parallel 1 (CORA) Autoimmunity and autoinflammation Chair: Maurizio Cutolo (Italy) Introduction: Maurizio Cutolo (Italy) Can Silicone breast implant be considered safe? YES: Franco Bassetto, Italy NO: Yehuda Shoenfeld, Israel + 3 oral presentations	Parallel 2 (CORA) Systemic sclerosis Chair: R Giacomelli (Italy) Introduction: R. Giacomelli Is it possible to determine which patients benefit most from nintedanib and which from immunosuppressants in SSc-ILD? YES: M Matucci Cerinic (Italy) NO: Y Allanore (France) + 3 oral presentations		
CEST (UTC+2 Paris, Amsterdam, Berlin) 13:00–14:15 hours / EDT (UTC-4 New York, Montreal) 7:00 – 8:00 hours / CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours				
13:15-14:15 Networking Break, Exhibition & Poster Viewing + Short Oral Discussions		13:00-14:15 Industry Symposium		

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

CEST (UTC+2 Paris, Amsterdam, Berlin) 14:15–15:45 hours / EDT (UTC-4 New York, Montreal) 8:15 – 9:45 hours / CST (UTC+8 Beijing, Manila, Perth) 20:15 – 21:45 hours

Plenary 3: How common is clinical remission in the real life? Experience from all around the world

Chair: R Van Vollenhoven (NL)

Introduction: R. Van Vollenhoven (NL)

Italy: Andrea Doria, The Netherlands: AE. Voskuijl, USA: M Petri, Latin America: MF Ugarte-Gil, Real life experiences from Hong Kong: CC Mok, Asia-Pacific: M Nikpour

Panel discussion and summary: A Doria, AE. Voskuijl, M Petri, MF Urgate Gill, CC Mok, M Nikpour

Summary: R Van Vollenhoven (NL)

CEST (UTC+2 Paris, Amsterdam, Berlin) 15:45–16:15 hours / EDT (UTC-4 New York, Montreal) 9:45 – 10:15 hours / CST (UTC+8 Beijing, Manila, Perth) 21:45 – 22:15 hours

Industry Symposium

Industry Symposium

CEST (UTC+2 Paris, Amsterdam, Berlin) 16:15–16:45 hours / EDT (UTC-4 New York, Montreal) 10:15 – 10:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:15 – 22:45 hours

Networking Break, Exhibition & Poster Viewing + Short Oral Discussions

CEST (UTC+2 Paris, Amsterdam, Berlin) 16:45–18:45 hours / EDT (UTC-4 New York, Montreal) 10:45 – 12:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:45 – 00:45 hours

Parallel 5 SLE

Precision and personalized Medicine

Chairs: G. Bertsias (GR); Chaim Putterman (US)

1. Stratification of Lupus and Systemic Autoimmune Diseases: Clinical Utility. Marta Alarcón Riquelme (ES)
 2. How far away is precision medicine for SLE? Joan Merrill (US)
 3. How close are we to personalised medicine for SLE? Ian Bruce (UK)
- +3 oral presentations

Parallel 6 SLE

Cardiovascular (and vascular) risk management

Chairs: A. Rahman (UK), D Wallace (US)

1. Cardiovascular disease in SLE: the contribution of lupus associated risk factors. E Svenungsson (SE)
 2. [New] EULAR Recommendations for cardiovascular risk management in SLE and APS. M Tektonidou (GR)
 3. Thrombosis in systemic lupus erythematosus. J Sanchez-Guerrero (CA)
- +3 oral presentations

Parallel 7 SLE

Early SLE

Chairs: M. Urowitz (CA); L. Sousa-Inês (PT)

1. Early lupus manifestations: when UCTD become SLE. Marta Mosca (IT)
 2. The Winding Road to Lupus: How can some avoid the destination? Judith James (US)
 3. Systemic lupus, big data & digital medicine: where do we stand? L Arnaud (FR)
- +3 oral presentations

Parallel 3 (CORA)

Rheumatoid arthritis

Chair: C Montecucco (Italy)

Does RA seropositivity counts in disease and therapeutic outcome?
 YES: seropositive and seronegative patients are different, respond to different therapies, have different clinical manifestations, even genetics
 Josef Smolen, Austria
 NO: they are the same
 Roberto Caporali, Italy
 +3 oral presentations

Parallel 4 (CORA)

Systemic sclerosis 2

Chair: G Szucs (HU)

Can we always distinguish PAH (group I) from group 3 PH in SSc patients?
 YES: Luc Mouthon, France
 No: Cosimo Bruni, Italy
 +3 oral presentations

CEST (UTC+2 Paris, Amsterdam, Berlin) 18:45–19:45 hours / EDT (UTC-4 New York, Montreal) 12:45 – 13:45 hours / CST (UTC+8 Beijing, Manila, Perth) 00:45 – 01:45 hours

Meet the Professor 3

Biologics in SLE

Americas: J Merrill (US)

Meet the Professor 4

The standard of care in SLE

Americas: M. Urowitz (CA)

Workshop 3

Lupus nephritis

Americas: M Dall’Era (US)

Workshop 4

Cutaneous lupus lesions

Americas: VP Werth (US)

Meet professor (CORA) 2

Autoinflammatory diseases

Paolo Sfriso (IT)

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

Friday, 8 October 2021

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 08:00–09:00 hours / EDT (UTC-4 New York, Montreal) 2:00 AM – 3:00 AM / CST (UTC+8 Beijing, Manila, Perth) 14:00 – 15:00 hours				
Meet the Professor 5 Molecules in the development in SLE therapy R. Van Vollenhoven (NL)	Meet the Professor 6 Unmet needs in SLE: how do we assess it? E Morand (AU)	Workshop 5 Anti-Rheumatic treatment before and during pregnancy R Fischer-Betz (DE) and Isabell Haase (DE)	Workshop 6 Cardio-pulmonary manifestations D. D’Cruz (UK)	Late Breaking Abstracts 2021
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours / EDT (UTC-4 New York, Montreal) 3:00 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours				
Plenary 4 The time has come to set up diagnostic criteria in SLE? Chair: M Mosca (Italy) Introduction: M. Mosca Yes: G Bertias (GR) Vs. No: M Aringer (DE) Panel discussion Summary: M Mosca (Italy)				
CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–11:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 5:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 17:00 hours				
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions				
CEST (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00 hours / EDT (UTC-4 New York, Montreal) 5:00 – 7:00 hours / CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours				
Parallel 8 SLE Antiphospholipid antibody syndrome and SLE Chairs: Y Shoenfeld (IS), R Cervera (ES) 1. Antiphospholipid antibodies and damage in SLE: the changing paradigm. G Ruiz-Irastorza (ES) 2. Long term follow-up of APS patients. N Agmon-Levin (IS) 3. Peptide therapies for antiphospholipid syndrome. A Rahman (UK) +3 oral presentations	Parallel 5 (CORA) Spondylarthritis Chair: Roberta Ramonda (IT) Did the understanding and treatment of non-radiographic axSpA add anything to our management of spondylarthritis? YES: nr-axSpA gave a new view new drugs etc Xenophon Baraliakos, (Germany) NO: we did not learn anything advanced axSpA is the same Dennis McGonagle, (UK) +3 oral presentations	Parallel 6 (CORA) COVID/Vaccination Chair: Howard Amital (IS) Can patients with AIDs be vaccinated and when? Marc Bijl, (The Netherlands) Different types of COVID vaccinations: are they all the same? PL Meroni (IT) Post COVID/vaccination syndrome: is it a reality? Michael Ehrenfeld (Israel) +3 oral presentations		
CEST (UTC+2 Paris, Amsterdam, Berlin) 13:00–14:15 hours / EDT (UTC-4 New York, Montreal) 7:00 – 8:00 hours / CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours				

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

13:15-14:15 Networking Break, Exhibition & Poster Viewing + Short Oral Discussions			13:00-14:15 Industry Symposium				
CEST (UTC+2 Paris, Amsterdam, Berlin) 14:15–16:15 hours / EDT (UTC-4 New York, Montreal) 8:15 – 10:15 hours / CST (UTC+8 Beijing, Manila, Perth) 20:15 – 22:15 hours							
Parallel 9 SLE: Biomarkers Chairs: Dimitrios Bogdanos (GR), J Buyon (US) 1. Clinical and Multiomics Studies of SLE. Sang-Cheol Bae (South Korea) 2. Useful biomarkers for early diagnosis of SLE. C Putterman (US) 3. Biomarkers for lupus nephritis. R Cervera (ES) +3 oral presentations		Parallel 10 SLE: Pipeline molecules in SLE Chairs: David Wofsy (US), R Van Vollenhoven (NL) 1. Overview of the 2021 pipeline molecules in SLE. Richard Furie (US) 2. Baricitinib. Yoshiya Tanaka, Japan 3. CD40/CD40L in SLE. Josef Smolen (AT) +3 oral presentations		Parallel 11 SLE: Lupus nephritis – clinical aspects Chairs: F. Houssiau (BE), BH Rovin (US) 1. New Approvals and New Guidelines on Lupus Nephritis – Clarity or Confusion? Tak Mao Chan (Hong Kong) 2. Clinical and histological features able to predict long term lupus nephritis prognosis. Gabriella Moroni, Italy 3. Lupus nephritis = chronic kidney disease: implications for management. Hans-Joachim Anders (Germany) 4. What is remission and what does it mean in terms of longer-term clinical benefit? David Jayne, UK			
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:15–16:45 hours / EDT (UTC-4 New York, Montreal) 10:15 – 10:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:15 – 22:45 hours							
Industry Symposium							
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:45–17:15 hours / EDT (UTC-4 New York, Montreal) 10:45 – 11:15 hours / CST (UTC+8 Beijing, Manila, Perth) 22:45 – 23:15 hours							
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions							
CEST (UTC+2 Paris, Amsterdam, Berlin) 17:15–19:15 hours / EDT (UTC-4 New York, Montreal) 11:15 – 13:15 hours / CST (UTC+8 Beijing, Manila, Perth) 23:15 – 01:15 hours							
Parallel 12 SLE: New clues in SLE pathogenesis Chairs: Z Amoura (FR), G Tsokos (USA) 1. The epigenetic contribution to SLE. Lindsey Criswell (USA) 2. The role of the interferon system in SLE. L Rönnblom (SE) 3. The role of bone marrow in the pathogenesis of SLE. DT Boumpas (GR) +3 oral presentations		Parallel 13 SLE: How do we integrate available biologics in SoC? Chairs: J Smolen (AT), R. Furie (USA) 1. 10 years of belimumab (2011-2021): what have we learned so far? L Iaccarino (IT) 2. B cell depletion works in SLE: how we should correctly deliver it. D Isenberg (UK) 3. IFN blockade in SLE: where are we now, and what does the future hold? E. Morand (Australia) +3 oral presentations		Parallel 14 SLE: Skin Chairs: E Bonfá (BR) G Girolomoni, (IT) 1. The tamed wolf ...! Management of refractory cutaneous lupus erythematosus. A Kuhn (DE) 2. Translational studies in CLE and CLE/SLE. V Werth (USA) 3. Photosensitivity: mechanisms and treatment. J Kahlenberg (USA) +3 oral presentations		Parallel 7 (CORA): COVID/Vaccination Chair: A Iagnocco (IT) Is post-COVID syndrome an autoimmune disease? YES: Yehuda Shoenfeld, Israel NO: Agostino Riva, Italy +3 oral presentations	Parallel 8 (CORA): Sjögren syndrome Chair: R Gerli (IT) Is salivary gland biopsy mandatory in Sjögren Syndrome? YES: Thomas Dörner, Germany NO: A.G. Tzioufas (Greece) +3 oral presentations
CEST (UTC+2 Paris, Amsterdam, Berlin) 19:15–20:15 hours / EDT (UTC-4 New York, Montreal) 13:15 – 14:15 hours/ CST (UTC+8 Beijing, Manila, Perth) 01:15 – 02:15 hours							
Meet the Professor 7		Meet the Professor 8		Workshop 7 Management of lupus pregnancies	Workshop 8	Meet professor (CORA) 4 Cannabis: a friend or a foe?	

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

What should we measure in clinical practice in SLE patients? Americas: MF Ugarte-Gil (Peru)	Molecules in the development in SLE therapy Americas: D Wallace (US)	Angela Tincani (Italy)	Cardio-pulmonary manifestations Americas: M Petri (US)	Piercarlo Sarzi-Puttini (IT)
---	--	------------------------	--	------------------------------

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

Saturday, 9 October 2021

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:30–10:30 hours / EDT (UTC-4 New York, Montreal) 3:30 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:30 – 16:30 hours				
Meet the Professor 9 The standard of care in SLE M. Govoni, Ferrara (IT)	Meet the Professor 10 Why is everything autoimmune until proven otherwise? Y Shoenfeld (IS)	Workshop 9 Neuropsychiatric lupus DT. Boumpas (GR)	Workshop 10 Musculoskeletal manifestations in SLE L Iaccarino (IT)	Meet professor (CORA) 5 Systemic sclerosis: what is new? R. Giacomelli (IT)
CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–12:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 6:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 18:00 hours				
Plenary 5: Is it safe to withdraw a low-dose-glucocorticoid in SLE patients in remission? Chair: R Cervera (Spain) Introduction: R Cervera Yes G. Ruiz-Irastorza (Spain) vs. No Z. Amoura (FR) Panel discussion Summary: R. Cervera Chair: R Cervera (Spain)				
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:00–12:30 hours / EDT (UTC-4 New York, Montreal) 6:00 – 6:30 hours / CST (UTC+8 Beijing, Manila, Perth) 18:00 – 18:30 hours				
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions				
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:30–14:30 hours / EDT (UTC-4 New York, Montreal) 6:30 – 8:30 hours / CST (UTC+8 Beijing, Manila, Perth) 18:30 – 20:30 hours				
Parallel 15 SLE New clues in LN pathogenesis Chair: A Davidson (USA), T. Dörner, Berlin (DE) 1. Pseudo-antiviral immunity drives LN: is IFN the right target even for LN. HJ Anders (DE) 2. The importance of immune and local factors in the expression of kidney injury G Tsokos (USA) 3. The role of pentraxin in LN – more than a biomarker? M Gatto (IT) +3 oral presentations	Parallel 16 SLE Difficult-to-manage- SLE manifestations Chairs: C. Vasconcelos, Porto (PT), GS Alarcón (USA) 1. Refractory SLE manifestations. Dario Roccatello; Italy 2. Fatigue in SLE. Matthias Schneider, Germany 3. Autoinflammatory manifestations in SLE. Raquel Faria, Portugal + 3 oral presentations	Parallel 9 (CORA) Rheumatoid arthritis Chair: F Atzeni (IT) Can Pain and Fatigue in RA patient. Are small molecules better than biologics? YES: small molecules better P Sarzi-Puttini (IT) NO: biologics better D Aletaha (AU) + 3 oral presentations	Parallel 10 (CORA) Autoimmunity and autoinflammation Chair: G Nagy (HU) Can autoimmunity and autoinflammation be separated? YES: there are two endpoints, phenotypic differences: Z Szekanecz (HU) NO: there is no such distinction: C Chizzolini (SW) + 3 oral presentations	

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

CEST (UTC+2 Paris, Amsterdam, Berlin) 14:30–15:30 hours / EDT (UTC-4 New York, Montreal) 8:30 – 9:30 hours / CST (UTC+8 Beijing, Manila, Perth) 20:30 – 21:30 hours

Networking Break, Exhibition & Poster Viewing + Short Oral Discussions

CEST (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours / EDT (UTC-4 New York, Montreal) 9:30 – 11:30 hours / CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<p>Parallel 17 SLE Management of SLE: what are we missing? Chairs: D. Boumpas (GR), D Wallace (USA) 1. Lupus in 2030: Successes and Challenges. David Wofsy (USA) 2. Who cares? Quality of Care in SLE. Anna Kernder-Stupnanek (DE) 3. Can biologics improve the quality of life in SLE patients? I Parodis (SE) + 3 oral presentations</p>	<p>Parallel 18 SLE Pregnancy Chairs: A Tincani (Italy), R Fischer-Betz (DE) 1. Pre-pregnancy counselling in women with SLE. Laura Andreoli (Italy) 2. Can we predict and prevent pregnancy complications in patients with lupus and APS? Jane Salmon (USA) 3. Positing the innate immune system at heart of the matter in neonatal lupus and application to new management strategies. Jill Buyon, USA + 3 oral presentations</p>	<p>Parallel 11 (CORA) Spondylarthritis Chair: P Sarzi-Puttini (IT) Psoriatic arthritis joints or skin: which drives the treatment?? Joints. Ian Bruce (UK) Skin. G Girolomoni (IT) + 3 oral presentations</p>	<p>Parallel 12 (CORA) Vasculitis Chair: F Schiavon (IT) Vasculitis: Is GCA and Takayasu the same? YES: the same. R Luqmani (UK) NO: differences between GCA-TA. C Salvarani (IT) + 3 oral presentations</p>
---	---	---	--

CEST (UTC+2 Paris, Amsterdam, Berlin) 17:30–19:00 hours / EDT (UTC-4 New York, Montreal) 11:30 – 13:00 hours / CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:00 hours

Plenary 6: When should targeted therapies be used in the treatment of lupus nephritis?

Chair: F. Houssiau (BE)
 Introduction: F. Houssiau (BE)
 Early in the disease course. Maria Dall’Era, USA vs.
 Only in refractory patients. BH Rovin, USA
 Panel discussion
 Summary: F. Houssiau (BE)

CEST (UTC+2 Paris, Amsterdam, Berlin) 19:00–19:30 hours / EDT (UTC-4 New York, Montreal) 13:00 – 13:30 hours / CST (UTC+8 Beijing, Manila, Perth) 01:00 – 01:30 hours

Congress Roundup Session (LIVE)